Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Atrial fibrillation; Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms RE-LY
- Sponsors Boehringer Ingelheim
- 01 Dec 2017 Status changed from recruiting to completed.
- 18 Sep 2017 Planned End Date changed from 9 Aug 2017 to 30 Oct 2017.
- 18 Sep 2017 Planned primary completion date changed from 9 Aug 2017 to 30 Oct 2017.